BTZO-15 Ameliorates Chemically Induced Colitis in Rats
Author Information
Author(s): Yukitake Hiroshi, Kimura Haruhide, Suzuki Hirobumi, Tajima Yasukazu, Sato Yoshimi, Imaeda Toshihiro, Kajino Masahiro, Takizawa Masayuki
Primary Institution: Takeda Pharmaceutical Company Limited
Hypothesis
BTZO-15, an active derivative of BTZO-1, can activate ARE-mediated gene expression and provide therapeutic effects in inflammatory bowel disease (IBD).
Conclusion
BTZO-15 shows promise as a novel therapeutic drug for IBD by activating cytoprotective gene expression and ameliorating colitis symptoms in rat models.
Supporting Evidence
- BTZO-15 induced expression of heme oxygenase-1 (HO-1), a protective protein, in the rectum of rats.
- Oral administration of BTZO-15 improved symptoms of DSS-induced colitis in a dose-dependent manner.
- BTZO-15 reduced ulcerated areas and rectal MPO activity in TNBS-induced colitis without affecting TNF-α levels.
Takeaway
Researchers found that a new drug called BTZO-15 can help treat a type of gut sickness in rats by making their bodies better at fighting off damage.
Methodology
The study involved administering BTZO-15 to rats with chemically induced colitis and measuring various health parameters, including body weight and rectal MPO activity.
Potential Biases
Potential bias due to the involvement of a pharmaceutical company in the study.
Limitations
The study was conducted only in rat models, and further research is needed to confirm the effects in humans.
Participant Demographics
Male F344/Du rats were used in the study.
Statistical Information
P-Value
p≤0.01
Statistical Significance
p≤0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website